Airway-Rehydrating agents for the treatment of cystic fibrosis: Past, present, and future

Annals of Pharmacotherapy

Volumn 45, Issue 1, 2011, Pages 49-59

  Pettit, Rebecca S ^a   Johnson, Cary E ^b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cystic fibrosis; Denufosol; Hypertonic saline; Inhaled mannitol; Lancovutide; Moli1901

Indexed keywords

ACETYLCYSTEINE; AMILORIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; COBIPROSTONE; COLISTIN; DENUFOSOL; DORNASE ALFA; GS 9411; IBUPROFEN; LANCOVUTIDE; MANNITOL; PLACEBO; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHLORIDE; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ARTICLE; BREATHING EXERCISE; BRONCHOSPASM; CHEST TIGHTNESS; COST BENEFIT ANALYSIS; COUGHING; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FUNCTION; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SPUTUM; THORAX PAIN; THROAT DISEASE; THROAT NUMBNESS; WHEEZING;

ADULT; CHILD; CYSTIC FIBROSIS; HUMANS; REHYDRATION SOLUTIONS; RESPIRATORY MUCOSA; RESPIRATORY SYSTEM; RESPIRATORY SYSTEM AGENTS; SALINE SOLUTION, HYPERTONIC;

EID: 78751485510     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P428     Document Type: Article

References (42)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373:1891-904. DOI 10.1016/S0140-6736(09)60327-5
2. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69. DOI 10.1164/rccm.200705-664OC (Pubitemid 350127838)
3. Marks JH. Airway clearance devices in cystic fibrosis. Paediatr Respir Rev 2007;8:17-23. DOI 10.1016/j.prrv.2007.02.003 (Pubitemid 46523787)
4. Flume PA, Robinson KA, O'Sullivan BP, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009;54:522-37.
5. Millis RM, Young RC, Kulczycki LL. Validation of therapeutic bronchoscopic bronchial washing in cystic fibrosis. Chest 1977;71:508-13. DOI 10.1378/chest.71.4.508
6. Ratjen F, Bush A. Amiloride: still a viable treatment option in cystic fibrosis? Am J Respir Crit Care Med 2008;178:1191-3.
7. Hirsh AJ, Zhamg J, Zamurs A, et al. Pharmacological properties of N- (3,5-diamino-6-chloropyrazine-2-carbonyl-N¢- 4-[4-(2,3-dihydroxypropoxy) phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008;325:77-88. DOI 10.1124/jpet.107.130443 (Pubitemid 351439164)
8. Jones AM, Helm JM. Emerging treatments in cystic fibrosis. Drugs 2009;69:1903-10.
9. Fibrosis Foundation. A "surf session" for babies? http://www.cff.org/aboutCFFoundation/Publications/connections/archive/ JulyAugust2009/Hypertonic-Saline.cfm (accessed 2010 Aug 29).
10. Taylor LM, Kuhn RJ. Hypertonic saline treatment of cystic fibrosis. Ann Pharmacother 2007;41:481-4. DOI 10.1345/aph.1H425 (Pubitemid 46536040)
11. Tarran R, Donaldson S, Boucher RC. Rationale for hypertonic saline therapy for cystic fibrosis lung disease. Semin Respir Crit Care Med 2007;28:295-302. DOI 10.1055/s-2007-981650 (Pubitemid 46982060)
12. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2009:CD001506. DOI 10.1002/14651858.CD001506.pub313
13. Havasi V, Hurst CO, Briles TC, et al. Inhibitory effects of hypertonic saline on P. aeruginosa motility. J Cyst Fibros 2008;7:267-9. DOI 10.1016/j.jcf.2007.11.009
14. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-3.
15. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83. (Pubitemid 26098513)
16. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-50.
17. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40. DOI 10.1056/NEJMoa04390018
18. Dellon EP, Donaldson SH, Johnson R, Davis SD. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol 2008;43:1100-6. DOI 10.1002/ppul.20909
19. Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS). http://www.clinicaltrials.gov/ct2/show/NCT00709280?term=hypertonic+saline& rank=38 (accessed 2010 Jan 29).
20. 7% Pre-mixed hypertonic saline flyer. www.cfservicespharmacy.com (accessed 2010 Mar 9).
21. Anderson SD, Brannan J, Spring J, et al. A new method for bronchialprovocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997;156:758-65.
22. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159:1843-8.
23. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133:1388-96. DOI 10.1378/chest.07-2294 (Pubitemid 351892995)
24. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999;14:678-85.
25. Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010;65:51-6. DOI 10.1136/thx.2009.116970
26. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997;88:553-60.
27. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-36.
28. Daviskas E, Anderson SD, Jaques A, Charlton B. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 2009;137:861-8. DOI 10.1378/chest.09-2017
29. Bilton D, Robinson P, Cooper P, Charlton B. Randomized, double blind, placebo-controlled Phase III study of inhaled dry powder mannitol (Bronchitol) in CF. Pediatr Pulmonol 2009;44(suppl 32):286.
30. Minasian C, Wallis C, Metcalfe C, Bush A. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 2008;43:1078-84. DOI 10.1002/ppul.20903
31. Daviskas E, Anderson SD, Eberl S, Young IH. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008;31:765-72. DOI 10.1183/09031936.00119707
32. Yerxa BR, Sabater JR, Davis CW, et al. Pharmacology of INS37217 [P(1)-(uridine 5¢)-P(4)- (2¢-deoxycytidine 5¢)tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther 2002;302:871-80. DOI 10.1124/jpet.102.035485 (Pubitemid 34920206)
33. Kellerman D, Rossi Mospan A, Engels J, Schaberg A, Gorden J, Smiley L. Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. Pulm Pharmacol Ther 2008;21:600-7. DOI 10.1016/j.pupt.2007.12.003 (Pubitemid 351970709)
34. Deterding R, Retsch-Bogart G, Milgram L, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005;39:339-48. DOI 10.1002/ppul.20192 (Pubitemid 40411534)
35. Smiley L, Rossi A, Mathews D, et al. Denufosol tetrasodium inhalation solution: results from two phase 2 trials in CF patients with mild to moderate lung disease (abstract 47). J Cyst Fibros 2006;5:S11.
36. Deterding RR, Lavange LM, Engels JM, et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007;176:362-9. DOI 10.1164/rccm.200608-1238OC (Pubitemid 47267470)
37. Moss R, Anbar R, Wilmott R, et al. Phase 3 study of denufosol tetrasodium for the treatment of cystic fibrosis. Presented at: American Thoracic Society 2009 International Conference, San Diego, CA, May 15-20, 2009.
38. Clunes MT, Boucher RC. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. Curr Opin Pharmacol 2008;8:292-9. DOI 10.1016/j.coph.2008.04.006
39. Zeitlin PL, Boyle MP, Guggino WB, Molina L. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004;125:143-9.
40. Grasemann H, Stehling F, Brunar H, et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007;131:1461-6. DOI 10.1378/chest.06-2085 (Pubitemid 46762353)
41. Studies of lancovutide in cystic fibrosis. http://www.lantibio.com/ lantibio-moli1901-cf-studies.htm (accessed 2010 Mar 8).
42. Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults with Cystic Fibrosis. http://www.clinicaltrials.gov/ct2/show/NCT00671736? term=lancovutide&rank=1 (accessed 2010 Mar 8).